FDA Approves Leqembi for Alzheimer's Disease Treatment
The U.S. Food and Drug Administration (FDA) has approved Leqembi (lecanemab-irgb) for the treatment of Alzheimer's disease. The approval follows clinical trial results demonstrating the drug's ability to slow disease progression.
The U.S. Food and Drug Administration (FDA) has granted full approval to Leqembi (lecanemab-irgb) for the treatment of Alzheimer's disease. The medication is a product of collaboration between Japan-based Eisai Inc. and U.S.-based Biogen.
The approval is based on findings from the Phase 3 Pioneer trial, which showed that Leqembi significantly slowed the progression of early-stage Alzheimer's disease. The drug targets the accumulation of amyloid-beta plaques in the brain, a hallmark of Alzheimer's pathology.
Leqembi's approval marks a significant advancement for patients with Alzheimer's, offering a new therapeutic option to slow the disease's course. The FDA's decision paves the way for further advancements and research in the field.